[{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"ea11b224-f9b4-42a8-b2f1-ec4f488885da","acronym":"PORTAL","url":"https://clinicaltrials.gov/study/NCT04400357","created_at":"2021-01-18T21:13:46.986Z","updated_at":"2024-07-02T16:36:11.094Z","phase":"Phase 3","brief_title":"Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors","source_id_and_acronym":"NCT04400357 - PORTAL","lead_sponsor":"Ruijin Hospital","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 244","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 10/07/2022","primary_completion_date":" 10/07/2022","study_txt":" Completion: 11/30/2022","study_completion_date":" 11/30/2022","last_update_posted":"2022-05-03"},{"id":"8a3236a7-dca6-4f5e-9c01-be7ddc571016","acronym":"","url":"https://clinicaltrials.gov/study/NCT00987766","created_at":"2021-01-18T03:51:32.039Z","updated_at":"2024-07-02T16:37:20.284Z","phase":"Phase 1","brief_title":"Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer","source_id_and_acronym":"NCT00987766","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" KRAS • CDH1 • VIM","pipe":"","alterations":" ","tags":["KRAS • CDH1 • VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gemcitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 07/01/2013","primary_completion_date":" 07/01/2013","study_txt":" Completion: 10/01/2016","study_completion_date":" 10/01/2016","last_update_posted":"2017-07-02"}]